Corcept Therapeutics Incorporated (CORT) Earnings History
Earnings Pressure23 years of earnings data (2003–2025) · 5-year EPS trend is negative
Loading earnings history...
Corcept Therapeutics Incorporated (CORT) Earnings Overview
As of July 7, 2026, Corcept Therapeutics Incorporated (CORT) reported trailing twelve-month net income of $48M, reflecting -33.3% year-over-year growth. The company earned $0.46 per diluted share over the past four quarters, with a net profit margin of 13.1%.
Looking at the long-term picture, CORT's 5-year EPS compound annual growth rate (CAGR) stands at -0.7%, signaling declining earnings. The company achieved its highest annual net income of $140M in fiscal 2024.
Corcept Therapeutics Incorporated maintains positive profitability with a gross margin of 98.3%, operating margin of 5.9%, and net margin of 13.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), HRMY ($146M net income, 18.3% margin), SUPN (-$29M net income, -5.4% margin), CORT has room to improve margins relative to the peer group. Compare CORT vs INVA →
CORT Earnings vs Peers
Earnings metrics vs comparable public companies
CORT Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $100M | -28.7% | $45M | $0.82 | 13.1% | 5.9% |
| 2024 | $140M | +31.6% | $137M | $1.23 | 20.7% | 20.3% |
| 2023 | $106M | +4.7% | $107M | $0.94 | 22.0% | 22.2% |
| 2022 | $101M | -9.9% | $113M | $0.87 | 25.2% | 28.0% |
| 2021 | $113M | +6.1% | $124M | $0.89 | 30.7% | 34.0% |
| 2020 | $106M | +12.6% | $128M | $0.85 | 30.0% | 36.2% |
| 2019 | $94M | +24.9% | $112M | $0.77 | 30.7% | 36.4% |
| 2018 | $75M | -41.6% | $89M | $0.60 | 30.0% | 35.6% |
| 2017 | $129M | +1486.3% | $53M | $1.04 | 81.1% | 33.2% |
| 2016 | $8M | +227.0% | $10M | $0.07 | 10.0% | 12.5% |
| 2015 | -$6M | +79.6% | -$3M | $-0.06 | -12.7% | -6.8% |
| 2014 | -$31M | +31.8% | -$28M | $-0.31 | -118.2% | -104.0% |
| 2013 | -$46M | -20.9% | -$41M | $-0.46 | -444.3% | -400.7% |
| 2012 | -$38M | -17.6% | -$36M | $-0.41 | -1150.5% | -1096.8% |
| 2011 | -$32M | -24.6% | -$32M | $-0.39 | - | - |
| 2010 | -$26M | -28.8% | -$27M | $-0.38 | - | - |
| 2009 | -$20M | -0.5% | -$20M | $-0.38 | -69537.9% | -69827.6% |
| 2008 | -$20M | -73.3% | -$20M | $-0.43 | -9598.6% | -9420.6% |
| 2007 | -$12M | +53.5% | -$12M | $-0.34 | -2401.0% | -2540.5% |
| 2006 | -$25M | -23.8% | -$26M | $-1.09 | -8460.2% | -8701.4% |
| 2005 | -$20M | -29.3% | -$21M | $-0.89 | - | - |
| 2004 | -$16M | -58.3% | -$16M | $-0.84 | - | - |
| 2003 | -$10M | - | -$10M | $-1.13 | - | - |
Download Data
Export CORT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CORT — Frequently Asked Questions
Quick answers to the most common questions about buying CORT stock.
What is CORT earnings per share (EPS)?
CORT trailing twelve-month (TTM) diluted EPS is $0.46, reflecting -33.3% year-over-year growth. The 5-year EPS CAGR is -0.7%. Complete EPS history from 2003 to 2025 is available in the table on this page.
What is Corcept Therapeutics Incorporated's net income?
Corcept Therapeutics Incorporated (CORT) trailing twelve-month net income is $48M as of 2025. Earnings declined -33.3% year-over-year. Corcept Therapeutics Incorporated has been profitable for 10 consecutive years.
Is CORT profitable?
Yes, CORT is profitable with a TTM net income of $48M and a net profit margin of +13.1%. Corcept Therapeutics Incorporated has generated profits for 10 consecutive years.
What is CORT's earnings growth rate?
CORT compound annual EPS growth rates (CAGR): 1-Year: -33.3%, 3-Year: -2.0%, 5-Year: -0.7%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2003 to 2025.
What are CORT's profit margins?
Corcept Therapeutics Incorporated net profit margin is +13.1%, operating margin is +5.9%, and gross margin is +98.3%. Margins are within a typical range for the sector. Return on Equity is +15.0%.
Is CORT growing earnings?
CORT earnings are declining — EPS fell -33.3% year-over-year. TTM net income dropped to $48M. This contrasts with the 5-year CAGR of -0.7%.
What was CORT's best earnings year?
Corcept Therapeutics Incorporated's highest annual net income on record is $140M, achieved in fiscal year 2024. Earnings history on this page spans 2003 to 2025 and includes all annual and quarterly figures.
What were CORT's earnings last quarter?
CORT's most recent reported quarter was Q1 2026. Net income was $-31M with diluted EPS of $-0.30. For a full breakdown of all quarters, see the quarterly earnings table on this page.